Entacapone, sold under the brand name Comtan among others, is a catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa/carbidopa for the treatment of Parkinson’s disease. It helps prolong the effect of levodopa by reducing its breakdown, thereby improving motor control and reducing symptoms such as tremors, stiffness, and slow movement.
Parent: Entacapone
Parent: Entacapone
Parent: Entacapone
Impurities in Entacapone can arise due to chemical synthesis, degradation, or improper storage conditions. Regulatory agencies such as the FDA, EMA, and ICH enforce impurity limits to ensure drug safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Common and serious adverse reactions include:
Entacapone has been associated with mild liver enzyme elevations, but serious liver toxicity is rare. Regular liver function tests (LFTs) may be recommended in patients with pre-existing liver disease or those taking multiple medications that affect liver function.